What We're Reading: Page 175
Industry reads hand-picked by our editors
Jan 20, 2021
-
The Wall Street Journal
Janet Woodcock to Lead FDA on Interim Basis
-
The Washington Post
Elderly begin to drop out of Novavax vaccine trial to get Pfizer and Moderna shots
-
Evaluate Vantage
The pandemic releases its grip on clinical trials
-
Vanity Fair
How Trump's COVID Chaos Drowned the FDA in Junk Science
Jan 19, 2021
Jan 15, 2021
-
The Washington Post
Vaccine reserve was already exhausted when Trump administration vowed to release it, dashing hopes of expanded access
-
FiercePharma
Bristol Myers hematology chief Ahmed's out the door amid CAR-T missteps
-
Bloomberg
Pfizer to Cut Covid Vaccine Deliveries as It Renovates Factory
-
Financial Times
New Bayer drugs will not bridge revenue gap, says pharma head
Jan 14, 2021
-
Pink Sheet
Woodcock To Be Acting US FDA Commissioner, Leaving Agency in Stable, Capable Hands
-
POLITICO
Officials: Trump's promised $200 drug-discount cards won't happen
-
STAT
Former Merck employee arrested for stealing trade secrets on cancer research
-
Healthcare Dive
Talkspace to go public via SPAC in $1.4B deal
Jan 13, 2021
-
The Wall Street Journal
Cancer Death Rate in U.S. Falls by Largest Yearly Amount on Record
-
POLITICO
FDA fights for independence in Trump administration's final days
-
Evaluate Vantage
Merck & Co buys into Kras
-
The New York Times
Johnson & Johnson Expects Covid Vaccine Results Soon but Lags in Production
Jan 12, 2021
Jan 11, 2021
-
Barron's
Start-Up EQRx, Which Wants to Undersell the Drug Industry, Raises Another $500 Million
-
Reuters
Sanofi buys Kymab for up to $1.5 billion to expand in immunotherapy
-
STAT
FDA advisory panel meetings became "rarer and tougher" in 2020
-
Endpoints News
Editas Medicine's science head Albright leaves for new job just as biotech gets trial clearance for sickle cell therapy
Previous
